Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

681 ARTÍCULOS , VIENDO DEL 466 AL 480

A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment

Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT, Wingo TS, Hales CM, Gámez Tansey M, Goldstein DS, Abrol A, Calhoun VD, Goldstein FC, Hajjar I, Fagan AM, Galasko D, Edland SD, Hanfelt J, Lah JJ, Weinshenker D.

Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452.

Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease

Creese B, Ismail Z.

Alzheimers Res Ther. 2022 Jan 5;14(1):2. doi: 10.1186/s13195-021-00949-7.

Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease

Jiang J, Wang M, Alberts I, Sun X, Li T, Rominger A, Zuo C, Han Y, Shi K, Initiative FTADN.

Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2163-2173. doi: 10.1007/s00259-022-05687-y. Epub 2022 Jan 15.

Interactions Between Weight Loss and Plasma Neurodegenerative Markers for Determining Cognitive Decline Among Community-Dwelling Older Adults

Giudici KV, Guyonnet S, Morley JE, Nguyen AD, Aggarwal G, Parini A, Li Y, Bateman RJ, Vellas B, de Souto Barreto P; MAPT/DSA Group.

J Gerontol A Biol Sci Med Sci. 2022 Jun 1;77(6):1159-1168. doi: 10.1093/gerona/glac015.

Biomarkers with Plasma Amyloid β and Tau Protein Assayed by Immunomagnetic Reduction in Patients with Amnestic Mild Cognitive Impairment and Alzheimer's Disease

Lee PJ, Tsai CL, Liang CS, Peng GS, Lee JT, Tsai CK, Lin YK, Yang FC.

Acta Neurol Taiwan. 2022 Jun 30;31(2):53-60.

Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease

Lim YY, Maruff P, Barthélemy NR, Goate A, Hassenstab J, Sato C, Fagan AM, Benzinger TLS, Xiong C, Cruchaga C, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield PR, Morris JC, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network.

JAMA Neurol. 2022 Mar 1;79(3):261-270. doi: 10.1001/jamaneurol.2021.5181.

A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach

Jutten RJ, Thompson L, Sikkes SAM, Maruff P, Molinuevo JL, Zetterberg H, Alber J, Faust D, Gauthier S, Gold M, Harrison J, Lee AKW, Snyder PJ.

J Alzheimers Dis. 2022;86(2):511-524. doi: 10.3233/JAD-215098.

Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review

van der Schaar J, Visser LNC, Bouwman FH, Ket JCF, Scheltens P, Bredenoord AL, van der Flier WM.

Alzheimers Res Ther. 2022 Feb 10;14(1):31. doi: 10.1186/s13195-022-00971-3.

Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study

Sheng C, Yang K, He B, Du W, Cai Y, Han Y.

Alzheimers Res Ther. 2022 Feb 14;14(1):35. doi: 10.1186/s13195-022-00977-x.

Novel approaches to measuring neurocognitive functions in Alzheimer's disease clinical trials

Carlson S, Kim H, Devanand DP, Goldberg TE.

Curr Opin Neurol. 2022 Apr 1;35(2):240-248. doi: 10.1097/WCO.0000000000001041.

MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets

Liu S, Fan M, Zheng Q, Hao S, Yang L, Xia Q, Qi C, Ge J.

Biomed Pharmacother. 2022 Apr;148:112681. doi: 10.1016/j.biopha.2022.112681. Epub 2022 Feb 15.

Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study

Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Baret-Rose C, Tréluyer JM, Abdoul H, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe-Gillot L, Paccalin M, Robert P, Godefroy O, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A; BALTAZAR study group.

Alzheimers Dement. 2022 Dec;18(12):2537-2550. doi: 10.1002/alz.12613. Epub 2022 Feb 20.

The Microbiota-Gut-Brain Axis in Alzheimer's Disease: A Review of Taxonomic Alterations and Potential Avenues for Interventions

Murray ER, Kemp M, Nguyen TT.

Arch Clin Neuropsychol. 2022 Feb 22;37(3):595-607. doi: 10.1093/arclin/acac008.

Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions

Ma C, Hong F, Yang S.

Molecules. 2022 Feb 11;27(4):1210. doi: 10.3390/molecules27041210.

Exosomal MicroRNA-Based Predictive Model for Preclinical Alzheimer's Disease: A Multicenter Study

Jia L, Zhu M, Yang J, Pang Y, Wang Q, Li T, Li F, Wang Q, Li Y, Wei Y.

Biol Psychiatry. 2022 Jul 1;92(1):44-53. doi: 10.1016/j.biopsych.2021.12.015. Epub 2022 Jan 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias